

cador[®] Pathogen 96 QIAcube HT Kit, Part 1

Store QIAamp[®] 96 plates, buffers, and lyophilized carrier RNA at room temperature (15–25°C). Before use, lyophilized carrier RNA should be dissolved in Buffer AVE, and then added to Buffer VXL mixture as described in the *cador Pathogen HT Handbook*. Prepare a mixture of Buffer VXL, carrier RNA, internal control (if applicable), and proteinase K according to Table 1 immediately before starting a run. Unused carrier RNA dissolved in Buffer AVE should be immediately frozen in aliquots at –20°C. Do not subject aliquots of carrier RNA to more than 3 freeze–thaw cycles. QIAGEN[®] Proteinase K can be stored at room temperature; for long-term storage, or if the ambient temperature often exceeds 25°C, store at 2–8°C.

Further information

- *cador Pathogen 96 QIAcube HT Handbook*: www.qiagen.com/handbooks
- Safety Data Sheets: www.qiagen.com/safety
- Technical assistance: toll-free 00800-22-44-6000, or www.qiagen.com/contact

Notes before starting

- This protocol is for the purification of pathogen nucleic acids from fluid samples. See Table 2 for sample pretreatments.
- Do not overload the QIAamp membrane as this can lead to impaired nucleic acid extraction and/or performance in downstream assays. See the kit handbook for more information on handling various sample types.
- Avoid repeated freezing and thawing of samples as this may reduce nucleic acid yield and quality.
- Prepare Buffers ACB, AW1, and AW2, and carrier RNA according to the instructions in the *cador Pathogen 96 QIAcube HT Handbook*.
- Prepare a mixture of Buffer VXL, carrier RNA, internal control (if applicable), and proteinase K according to Table 1.

December 2013



- Ensure that the relevant version of the *cador* Pathogen 96 QIAcube HT.QSP run file is installed and that software version 4.17.1 or higher is installed. This is mandatory to process the *cador* Pathogen 96 QIAcube HT Kit.

Table 1. Preparation of Buffer VXL, carrier RNA, internal control (if applicable), and proteinase K mixture

| Samples | 8 | 16 | 24 | 32 | 40 | 48 | 56 | 64 | 72 | 80 | 88 | 96 |
|-----------------------|-----|-----|-----|-----|------|------|------|------|------|------|------|------|
| Buffer VXL (ml) | 1.4 | 2.1 | 2.7 | 3.4 | 4.0 | 4.6 | 5.3 | 5.9 | 6.6 | 7.2 | 7.8 | 8.5 |
| Proteinase K (µl) | 360 | 520 | 680 | 840 | 1000 | 1160 | 1320 | 1480 | 1640 | 1800 | 1960 | 2120 |
| Carrier RNA (µl) | 18 | 26 | 34 | 42 | 50 | 58 | 66 | 74 | 82 | 90 | 98 | 106 |
| Internal Control (µl) | 90 | 130 | 170 | 210 | 250 | 290 | 330 | 370 | 410 | 450 | 490 | 530 |

Table 2. Pretreatments (see the *cador* Pathogen 96 QIAcube HT Handbook for more details)

| Name | Application |
|-----------------|--|
| Pretreatment B1 | For difficult-to-lyse bacteria in whole blood or pretreated tissue |
| Pretreatment B2 | For difficult-to-lyse bacteria in body fluids |
| Pretreatment T1 | For mechanical disruption of tissue |
| Pretreatment T2 | For enzymatic digestion of tissue |
| Pretreatment F1 | For isolation of viral nucleic acids from feces |
| Pretreatment F2 | For isolation of bacterial and viral DNA from feces |

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual.

Trademarks: QIAGEN®, QIAamp®, QIAcube®, QIAextractor®, *cador*® (QIAGEN Group). 1080380 12/2013 © 2013 QIAGEN, all rights reserved.

